Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
30 Julio 2024 - 7:00AM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that it plans to release
financial results for the second quarter ended June 30, 2024 on
August 13, 2024. The Company will host a conference call at 8:30
a.m. E.T. on August 13, 2024, to provide a business update and
discuss financial results.
Tuesday, August 13, 8:30 a.m.
E.T.
Domestic: (877) 405-1242 International: (201) 389-0852 Webcast
Registration: Click Here
An archived version of the call will be available approximately
two hours after the completion of the event on the Marinus website
at ir.marinuspharma.com/events-and-presentations.
About Marinus Pharmaceuticals Marinus is a
commercial-stage pharmaceutical company dedicated to the
development of innovative therapeutics for seizure disorders. The
Company first introduced FDA-approved prescription medication
ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022. For
more information about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730576206/en/
Company Investors Sonya
Weigle SVP, IR, HR & Corporate Affairs Marinus Pharmaceuticals,
Inc. sweigle@marinuspharma.com
Media Molly Cameron Director,
Corporate Communications & Investor Relations Marinus
Pharmaceuticals, Inc. mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024
